Related Experiment Video
Updated: Aug 24, 2025

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
Published on: September 26, 2018
[New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects]
N A Dragomiretskaya1, A I Tarzimanova1, J S Kucherova1
1Sechenov First Moscow State Medical University (Sechenov University).
Abstract:
Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and antiproliferative effects, both cardiac and extracardiac. The article also discusses the possibility of using spironolactone in patients with the new coronavirus infection SARS-CoV-2 (COVID-19).
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management
Antihypertensive Drugs: Potassium-Sparing Diuretics
Heart Failure Drugs: Inotropic Agents
Antihypertensive Drugs: Direct Renin Inhibitors

